Role of vena cava filters for the management of cancer-related venous thromboembolism: Systematic review and meta-analysis.

Crit Rev Oncol Hematol

UROGIV Research Group, Universidad del Valle, Cali, Colombia; Associate Professor, School of Medicine, Universidad del Valle, Cali, Colombia.

Published: October 2018

AI Article Synopsis

  • The effectiveness of vena cava filters alone or with anticoagulation for preventing recurrent venous thromboembolism in cancer patients was examined.
  • A systematic search across multiple databases led to the inclusion of seven studies involving 35,333 patients, with most studies exhibiting a low risk of bias.
  • The results indicated that anticoagulation significantly reduced the risk of recurrent venous thromboembolism compared to vena cava filters, suggesting that filters offer no benefits for this patient population.

Article Abstract

Background: Results from cohort studies evaluating the benefit in prevention of recurrent Venous Thromboembolism in cancer population are heterogeneous and controversial.

Objective: To determine the effectiveness and harms of vena cava filters alone or combined with anticoagulation to prevent the risk of recurrent venous thromboembolism in patients with cancer-related venous thromboembolism.

Materials And Methods: A search strategy was conducted in the MEDLINE, CENTRAL, EMBASE and LILACS databases. Searches were also conducted in other databases and unpublished literature. Clinical trials were included without language restrictions. The risk of bias was evaluated with the Cochrane Collaboration's tool and a modified version for cohort studies. An analysis of fixed effects was conducted. The primary outcome was recurrent venous thromboembolism. The secondary outcomes were overall survival and adverse effects. The measure of the effect was the risk ratio with a 95% confidence interval.

Results: Seven studies were included in the qualitative and quantitative analysis. 35,333 patients were found among the seven studies. A low risk of bias was shown for most of the study items. The overall risk ratio (RR) for recurrent venous thromboembolism was 2.53 95%CI (1.35-4.75) favoring anticoagulation compared with vena cava filter.

Conclusion: Vena cava filter did not show benefits for recurrent venous thromboembolism prevention in the cancer-patients population.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2018.07.005DOI Listing

Publication Analysis

Top Keywords

venous thromboembolism
24
recurrent venous
20
vena cava
16
cava filters
8
cancer-related venous
8
cohort studies
8
risk bias
8
risk ratio
8
venous
7
thromboembolism
6

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!